topic

458 Immunologic niches of the central nervous system in a novel EGFR-mutant glioblastoma murine model of immunotherapeutic resistance
Katie B Grausam, Emily Hatanaka, Tahir B Dar, David Rincon Fernandez Pacheco, Joshua J Breunig, Stephen L Shiao

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A509; DOI: 10.1136/jitc-2023-SITC2023.0458
459 Treatment management of BRAF-mutant melanoma patients following tumor recurrence upon adjuvant therapy: A multicenter real-world cohort study from the prospective skin cancer registry ADOREG
Maximilian Haist, Henner Stege, Friederike Rogall, Yuqi Tan, Imke von Wasielewski, Kai Christian Klespe, Friedegund Meier, Peter Mohr, Katharina Kaehler, Michael Weichenthal, Dirk Schadendorf, Selma Ugurel, Elisabeth Livingstone, Georg Lodde, Lisa Zimmer, Ralf Gutzmer, Dirk Debus, Bastian Schilling, Alexander Kreuter, Jens Ulrich, Frank Meiss, Rudolf Herbst, Andrea Forschner, Ulrike Leiter, Claudia Pfoehler, Martin Kaatz, Fabian Ziller, Jessica Hassel, Michael Tronnier, Michael Sachse, Edgar Dippel, Patrick Terheyden, Carola Berking, Markus V Heppt, Felix Kieker, Sebastian Haferkamp, Christopher Gebhardt, Jan Simon, Stephan Grabbe, Carmen Loquai

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A510-A513; DOI: 10.1136/jitc-2023-SITC2023.0459
460 Efficacy of adding anti-PD1 immunotherapy to dabrafenib + trametinib (DT) at progression in BRAFv600e mutated anaplastic thyroid carcinoma (BRAFm-ATC)
Sarah Hamidi, Priyanka C Iyer, Maria K Gule-Monroe, Anastasios Maniakas, Ramona Dadu, Mark E Zafereo, Jennifer Wang, Naifa L Busaidy, Maria E Cabanillas

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A514; DOI: 10.1136/jitc-2023-SITC2023.0460
461 Co-targeting PD-L1 and CDK4/6 benefits plasticizer-associated early-onset breast cancer
Shu-Wei Hu, Wei-Chien Huang

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A515; DOI: 10.1136/jitc-2023-SITC2023.0461
462 Pre-selection of patients who would respond to combination of chemotherapy and low dose immunotherapy using human histoculture platform
Kowshik Jaganathan, Biswajit Das, BV Prakash, MS Ganesh, Amritha Prabha, Vijay Pillai, Ravi Krishnappa, V Syamkumar, Chandan Bhowal, M Mouniss, M Dharanidharan, M Rajashekar, M Oliyarasi, Ritu Malhotra, K Govindraj, Manjunath I Nandennavar, Shashidhar V Karpurmath, Mohit Malhotra, Nandini P Basak, Satish Sankaran

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A516; DOI: 10.1136/jitc-2023-SITC2023.0462
463 Targeting a novel myeloid checkpoint Siglec-15 in GBM generates an extremely durable response with Zika virus oncolytic therapy
Ashwani Kesarwani, Amanda De Andrade Costa, Tong Hu, Jeremy N Rich, Albert Kim, Pei-Yong Shi, Michael S Diamond, Milan Chheda

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A517; DOI: 10.1136/jitc-2023-SITC2023.0463
464 Integrin αvβ1 is expressed in multiple solid tumor types and drives the adhesion of cancer associated fibroblast to latent TGF-β
Vishal Kothari, Selorm Tamakloe, Colin Magowan, Gail Lee, Darren Finkelstein, Tim Hom, Manuel Munoz, Dennis Monteleone, Subramanian Karu, Erine Budi, Prerna Kotak, Shamra Martin, Katherine Jenkins, Martin Decaris, Tim Machajewski, Fernando Rock, Scott M Turner

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A518; DOI: 10.1136/jitc-2023-SITC2023.0464
465 Development of ex vivo 3D tumor models to aid in immuno-oncology drug discovery efforts
Katy A Lassahn, Ashley K Elrod, Natalie W Dance, Kimberly J Burgess, Danielle Nadeau, Aaron L Carlson, Melissa Millard, Michael J Wick, Teresa M DesRochers, Kathryn M Appleton

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A519; DOI: 10.1136/jitc-2023-SITC2023.0465
466 Combined inhibition of KRAS G12C and PD-1 boosts the therapeutic efficacy via conditioning of tumor microenvironment in pre-clinical humanized NSCLC mouse models
Ting Ni, Tongxin Huo, Yawen Zhang, Panpan Wang, Huacheng He, Jingjing Wang, Wenting Shi, Xiangnan Qiang, Qingyang Gu

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A520; DOI: 10.1136/jitc-2023-SITC2023.0466
467 A real-world retrospective study of immunotherapy in NSCLC patients with KRAS mutation
Huiping Qiang, Hua Zhong

Journal for ImmunoTherapy of Cancer Nov 2023, 11 (Suppl 1) A521; DOI: 10.1136/jitc-2023-SITC2023.0467

Main menu

topic

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

topic

Pages